|
| 35915964 | Association of Antibody Immunity With Cryptococcal Antigenemia and Mortality in a South African Cohort With Advanced Human Immunodeficiency Virus Disease. | Clin Infect Dis | 2023 |
| 37859995 | Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis. | Mayo Clin Proc Innov Qual Outcomes | 2023 |
| 37771088 | Shared and unique antibody and B cell profiles in HIV-positive and HIV-negative individuals with cryptococcal meningoencephalitis. | Med Mycol | 2023 |
| 37186922 | Misinterpretation of Clinical Research Findings and COVID-19 Mortality. | Ann Intern Med | 2023 |
| 36975207 | Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial. | Elife | 2023 |
| 37129285 | Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy. | Expert Rev Respir Med | 2023 |
| 36740590 | Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019. | Clin Infect Dis | 2023 |
| 35941021 | Rethinking the role of COVID-19 convalescent plasma in the critically ill. | Transfus Apher Sci | 2023 |
| 36227656 | Anorectal Testing for Mpox Virus Infection in Men Who Have Sex With Men With and Without Proctitis. | Clin Infect Dis | 2023 |
| 35076699 | Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis. | JAMA Netw Open | 2022 |
| 35348348 | <i>mBio</i> Welcomes Clinical Research Papers That Advance Our Understanding of Human-Microbe Interactions. | mBio | 2022 |
| 35635888 | Elucidating the role of procalcitonin as a biomarker in hospitalized COVID-19 patients. | Diagn Microbiol Infect Dis | 2022 |
| 36069882 | Convalescent Plasma for Covid-19. | N Engl J Med | 2022 |
| 35896965 | Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1-August 20, 2021): a retrospective observational monocentric study. | BMC Infect Dis | 2022 |
| 36351430 | Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy. | Cell Rep Med | 2022 |
| 35952358 | Cryptococcal Antigen Screening and Missed Opportunities for Earlier Diagnosis Among People With HIV and Poor Virologic Control in the Bronx, NY. | J Acquir Immune Defic Syndr | 2022 |
| 34861088 | Is SARS-CoV-2 viral clearance in nasopharyngeal swabs an appropriate surrogate marker for clinical efficacy of neutralising antibody-based therapeutics? | Rev Med Virol | 2022 |
| 34901997 | Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial. | JAMA Intern Med | 2022 |
| 35262370 | COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. | Clin Microbiol Rev | 2022 |
| 35135758 | WHO covid-19 drugs guideline: reconsider using convalescent plasma. | BMJ | 2022 |
| 35076698 | Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma. | JAMA Netw Open | 2022 |
| 32843125 | Prevalence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in respiratory cultures and diagnostic performance of the MRSA nasal polymerase chain reaction (PCR) in patients hospitalized with coronavirus disease 2019 (COVID-19) pneumonia. | Infect Control Hosp Epidemiol | 2021 |
| 33883259 | Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts. | mSphere | 2021 |
| 33653885 | The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19. | mBio | 2021 |
| 33851144 | Understanding vaccine hesitancy in COVID-19. | Med | 2021 |
| 33905478 | Disease Severity and Durability of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Response: A View Through the Lens of the Second Year of the Pandemic. | Clin Infect Dis | 2021 |
| 33621214 | SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities. | J Clin Invest | 2021 |
| 33758875 | Functional Antibodies in COVID-19 Convalescent Plasma. | medRxiv | 2021 |
| 33552883 | Unexpected case of cryptococcal meningoencephalitis in a patient with long-standing well-controlled HIV infection. | Med Mycol Case Rep | 2021 |
| 34959485 | Extracellular Vesicles from Different Pneumococcal Serotypes Are Internalized by Macrophages and Induce Host Immune Responses. | Pathogens | 2021 |
| 34824251 | Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response. | Nat Commun | 2021 |
| 34756090 | Isolation and Characterization of Human Monoclonal Antibodies to Pneumococcal Capsular Polysaccharide 3. | Microbiol Spectr | 2021 |
| 34458391 | Post-severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Treatment Hospitalizations as a Sentinel for Emergence of Viral Variants in New York City. | Open Forum Infect Dis | 2021 |
| 34481804 | Risk factors associated with poor response to COVID-19 vaccination in kidney transplant recipients. | Kidney Int | 2021 |
| 34452459 | COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. | Viruses | 2021 |
| 34322562 | Evaluation of Clinical Outcomes After Introduction of a Dedicated Infectious Diseases-Critical Care Medicine Service in Critical Care Units. | Open Forum Infect Dis | 2021 |
| 34036587 | Use of convalescent plasma in COVID-19 patients with immunosuppression. | Transfusion | 2021 |
| 34061603 | A Structural Model for the Ligand Binding of Pneumococcal Serotype 3 Capsular Polysaccharide-Specific Protective Antibodies. | mBio | 2021 |
| 33958057 | The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. | Mayo Clin Proc | 2021 |
| 34164419 | Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. | Front Med (Lausanne) | 2021 |
| 33476300 | Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC. | JCI Insight | 2021 |
| 32805024 | Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy. | Clin Infect Dis | 2021 |
| 31342058 | Cryptococcus neoformans infection in Human Immunodeficiency Virus (HIV)-infected and HIV-uninfected patients at an inner-city tertiary care hospital in the Bronx. | Med Mycol | 2020 |
| 31988178 | Human IgM Inhibits the Formation of Titan-Like Cells in Cryptococcus neoformans. | Infect Immun | 2020 |
| 31740558 | Antimicrobial Therapy in the Context of the Damage-Response Framework: the Prospect of Optimizing Therapy by Reducing Host Damage. | Antimicrob Agents Chemother | 2020 |
| 31915082 | The damage response framework and infection prevention: From concept to bedside. | Infect Control Hosp Epidemiol | 2020 |
| 33458462 | Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis. | ACS Omega | 2020 |
| 33363284 | The Assessment of Convalescent Plasma Efficacy against COVID-19. | Med | 2020 |
| 33300012 | Treatment of Severe COVID-19 with Convalescent Plasma in the Bronx, NYC. | medRxiv | 2020 |
| 33177233 | In fatal COVID-19, the immune response can control the virus but kill the patient. | Proc Natl Acad Sci U S A | 2020 |